Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>What were your estimates for Tyzeka / Sebivo sales the first year?<

I was expecting better than $20M in the U.S. alone.

3Q06 sales of Baraclude were $22M (an $88M annual run rate) and that included only a partial quarter of sales in the UK, France, Germany, and Japan.

3Q06 sales of Hepsera—a clearly inferior drug—were $55M (a $220M annual run rate).

To reiterate: I hope JP’s $20M guidance is an intentionally lowball figure.